Boston, MA, July 10, 2019 --(PR.com)-- Since 2016, early impact investment funds have become an innovative investment management strategy to drive funds into research into climate change and the health sector.
According to research, the private sector has invested up to $159.9 billion in pharmaceutical research while a significant number of funds have been moved towards funding the $700 billion financial vacuum identified by the OECD for successful climate change prevention.
Some of these investments come fromearly-impact investment funds designed to balance corporate and public interests. Kenworthy Capital is one such recently founded early-stage impact investment fund This investment fund will focus on investing in public and private companies with a focus in two-areas:
- Autoimmune Diseases - More than 80 diseases occur as a result of the immune system attacking the body's own organs, tissues, and cells. Some of the more common autoimmune diseases include type 1 diabetes, celiac, rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease.
Although the causes of many autoimmune diseases remain unknown, a person's genes in combination with infections and other environmental exposures are likely to play a significant role in disease development. Treatments are available for many autoimmune diseases, but cures have yet to be discovered.*
- Climate Change – Climate change represents one of the greatest threats of our time. There is a wide variety of problem that needs addressing these include the social issues such as, alleviating the impact from climate change-induced extreme weather events, reducing air pollution in cities, addressing ocean plastics, transforming our energy system to clean energy or sustainable ways of food production, to providing access to quality education and healthcare. Supporting efforts in the public and private sector to address and solve the challenges of climate change is a core mission of Kenworthy Capital.
Among the various commitments that the company has made to the climate change and auto-immune disease prevention, is the commitment that a percentage of founders' income from the fund will be donated to non-profit based celiac research. Investors in the fund can also donate to research interests of their particular interest but all returns will be at the discretion of the individual investors.
When asked for a comment, a spokesperson had this comment to offer:
"Auto-immune disease and climate change represent a major threat to the American society. The lack of research and awareness of either of these issues puts us at risk of leaving the world in a worse position for our children and the coming generations. For this reason, Kenworthy Capital was initiated to help increase awareness and drive research efforts into tackling both of these concerns."
About Kenworthy Capital
Kenworthy Capital is an early stage impact investment fund that caters to climate change and auto-immune disease research. Contributing a part of incomes to either of these movements, Kenworthy Capital balances out financial returns with awareness efforts for the environment and public health. The fund was created by Inger and Randal Kenworthy to create investment returns while raising awareness of impact investing and the need for research in diseases like celiac.
Read the full story here: https://www.pr.com/press-release/789322
Press Release Distributed by PR.com
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.